NYSE
CI

Cigna Corporation

Shareholder Corporation Litigation

Rigrodsky & Long, P.A. Announces Investigation Of Cigna Corporation (NYSE: CI) Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Cigna Corporation (“Cigna” or the “Company”) (NYSE: CI) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Anthem, Inc. (“Anthem”) (NYSE: ANTM), in a transaction valued at approximately $54.2 billion.

Under the terms of the agreement, shareholders of Cigna will receive $103.40 in cash and 0.5152 shares of Anthem for each share of Cigna they own.  Based on Anthem’s closing price on July 23, 2015, Cigna shareholders would have received compensation valued at approximately $183.36 per share.

The investigation concerns whether Cigna’s board of directors failed to adequately shop the Company and obtain the best possible value for Cigna’s shareholders before entering into an agreement with Anthem.  According to Yahoo! Finance, at least one analyst has issued a price target for Cigna stock at $190.00 per share.

If you own the common stock of Cigna and purchased your shares before July 24, 2015, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.